by Raynovich Rod | Nov 6, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Strong Jobs Report Boosts Market–Treasuries Sell -Off with 10 Year up to 2.74% Volatile Week Finds Buyers-Technical Levels Hold 11/8/13 9:45 a Biotechnology stocks rebounded today with the IBB up 3% to $203.86. The sector hit a major downdraft yesterday but we...
by Raynovich Rod | Nov 1, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Equities: The Only Game in Town With Rates Under 3%? October, normally a month to be cautious on the market, proved that trends can be misleading even in the midst of turbulent times in Washington. DOW Up 2.5%, S&P Up 3.5%, NASDAQ Up 2.5%. Healthcare stocks...
by Raynovich Rod | Oct 29, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Dow, S&P and Biotech Sector Hit All Time Highs NASDAQ Still 1000+Pts Under 2000 High Levels After a 10% sell-off in early October many large cap biopharmaceutical and diagnostic stocks are at new highs with the major indices at or near their October highs. The...
by Raynovich Rod | Oct 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Have Recovered From Early October Lows We have been traveling for two weeks and have not posted new content nor made portfolio changes. Despite a significant correction in the biotech sector in early October when major ETFs (IBB) and funds such as the...
by Raynovich Rod | Oct 9, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Expect to be back by 10/25 in the meantime see previous two posts. Biotech stocks remain choppy. Hold mode with 10% cash. Big action has moved to Internets and new media. See Raynoreport.com for market updates. ________________…………...
by Raynovich Rod | Sep 25, 2013 | Clinical Diagnostics and Tools
Foundation Medicine (FMI) Soars on IPO-Up 75% Foundation Medicine (FMI $32.30), based in Cambridge MA, went public today at $18 offering 5,888,888 M shares and promptly went up 79% on volume over 4.5M shares as of early trading. See IPO Desktop for more information...
by Raynovich Rod | Sep 16, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
“Yellen” Effect Boosts Markets-FED Policies Clarified With Larry Summers dropping out as a likely candidate for FED Chairman the market may be assured of a continuation of current FED policy. The market sees no surprises in Janet Yellen who is a...
by Raynovich Rod | Sep 11, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
NASDAQ Struggling As AAPL Down 5%–IBB ($205.36) off 0.4% Near All Time High of $207.78 The market is trying to continue its resilience since the hits on Syria were postponed pending Russian efforts with Assad. The 10 Year Treasury had an A+ offering at...
by Raynovich Rod | Aug 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many “undertoads” remain such as weak economic data, taper...
by Raynovich Rod | Aug 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201....
